Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma.
Caroline RobertGeorgina V LongBenjamin BradyCaroline DutriauxAnna Maria Di GiacomoLaurent MortierPiotr RutkowskiJessica C HasselCatriona M McNeilEwa Anna KalinkaCeleste LebbèJulie CharlesMicaela M HernbergKerry Joane SavageVanna Chiarion SileniCatalin MihalcioiuCornelia MauchAna AranceFrancesco CognettiLars NyHenrik SchmidtDirk SchadendorfHelen J GogasJesús ZocoSandra RePaolo Antonio AsciertoVictoria AtkinsonPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
Results from this 5-year analysis confirm the significant benefit of nivolumab over dacarbazine for all end points and add to the growing body of evidence supporting long-term survival with nivolumab mono-therapy. Survival is strongly associated with achieving a durable response, which can be maintained after treatment discontinuation, even without subsequent systemic therapies.